Safety and clinical usage of newcastle disease virus in cancer therapy

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432

Induction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma

Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus

Current vaccination strategies for prostate cancer

Proving the principle: dendritic cell-based vaccines in urogenital cancers